Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. CRDF has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
CRDF stock price ended at $3.02 on Wednesday, after losing-18.38%
The Cardiff Oncology Inc stock price decreased by -18.38% on the last trading day (18 Jun 2025), dropping from 3.44 to 3.02. Throughout the last trading session, the stock experienced a fluctuation of 15.44% , ranging from a day low of $2.98 to a day high of 3.44. The price has declined in 5 of the last 10 days, resulting in a total change of -16.57% during this period. On the last day, trading volume increase by 2.31M shares, with the falling prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 3.73M shares were traded, amounting to approximately 11.74M.
CRDF Technical Signals
CRDF(Cardiff Oncology Inc Corp) has 4 buy signals and 5 sell signals now. The current trend is downtrend starting from 2025-06-11. The total price change during this trend is -21.86%. Recently, the price has decreased with an increase in volume, indicating a strong bearish signal. The average turnover of CRDF over the last 5 trading days is 5.33M. Overall, the technical indicator signals lean more toward a Neutral outlook in the mid-term.
CRDF Moving Average Analysis
Cardiff Oncology Inc's overall moving average trend leans more bearish as of Friday, June 20, 2025, with 2 negative signals and 2 positive signal. In the mid-term, the SMA_20 being above the SMA_60 signals a strong bullish trend. There will be some resistance from the lines at $4.575366666666667, and $5.110166666666666. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $2.844966666666666, and $2.3101666666666665. A break-down below any of these levels will issue sell signals.
CRDF Short Selling Analysis
The short sale ratio of Cardiff Oncology Inc(CRDF) as of 17 Jun 2025 is 11.77%, dropping from last trading day. With decreasing price from 3.86 to 3.70. The short sell activity indicate that short sellers may be anticipating price hit a bottom.
Technical Signal
Technical Signals Summary
Sell
5
Buy
4
Moving Average
Swing
Negative
Stock Price Below SMA_5
Short Term
Positive
SMA_5 Above SMA_20
Mid Term
Positive
SMA_20 Above SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
4 Bullish Signals
4 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Awesome Oscillator (5, 34)
AO_5_34 > 0
0.515
Bullish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 > 0
0.169
Bullish
Stochastic RSI %K (14, 14, 3, 3)
STOCHRSIk_14_14_3_3 < 20
3.073
Bullish
Williams %R (14 days)
WILLR_14 < -80
-97.143
Bullish
5 Bearish Signals
5 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
Indicators
Signal
Value
Meaning
Momentum (10 days)
MOM_10 < 0
-0.6
Bearish
Closing price
close < fibonacci_S1
3.02
Bearish
Moving Average
Price crosses below 20-day SMA
--
Bearish
Moving Average
Price crosses below 60-day SMA
--
Bearish
Moving Average
Price crosses below 200-day SMA
--
Bearish
CRDF Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to Cardiff Oncology Inc(CRDF), our algorithm predicts CRDF's 1-month price at $3.85, with an 1.06%upwardshift. Using a similarity score up to 98.43%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for Cardiff Oncology Inc (CRDF.O) stock, as of Sunday, June 15, 2025 , forecasts a 1.06% change over the next month, based on its high correlation with TRV.N stock patterns. The similarity between their price movements over the analyzed periods is 98.43%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
CRDF
No Data
TRV
Up: 1.06%Similarity: 98.43%
Name
Similarity
Up/Down
TRV.N
98.43%
+1.06%
OMER.O
98.39%
+48.41%
NOW.N
98.36%
+11.96%
LBTYA.O
98.23%
-4.57%
FDUS.O
98.21%
-1.52%
PROP.O
98.15%
-7.41%
CNTY.O
98.15%
-4.01%
KNSA.O
98.14%
-24.38%
IBKR.O
98.14%
+4.47%
PEN.N
98.12%
-8.99%
CRDF Seasonality Analysis
Based on CRDF's historical stock price data across all years, the probability of a positive return in June is27.27%, suggesting it maynotbe an ideal month to invest in CRDF. In contrast,Augustoffers the highest probability of positive returns at60.00%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Cardiff Oncology Inc (CRDF.O) stock in August has the highest probability of a positive return (60.00%), while June has the lowest probability (27.27%).
Performance Seasonality
The chart shows Cardiff Oncology Inc. (CRDF)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
People Also Watch
FAQ
Should I buy Cardiff Oncology Inc (CRDF.O) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. CRDF has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
Which months have the highest win rate for buying Cardiff Oncology Inc (CRDF.O) stock in a year?
The radar chart shows that buying Cardiff Oncology Inc (CRDF.O) stock in August has the highest probability of a positive return (60.00%), while June has the lowest probability (27.27%).
How has Cardiff Oncology Inc. (CRDF)'s stock price performed over the past three years?
CRDF's stock price rose by 0.00% in 2023,increased by 183.66% in 2024, and went down by 29.11% in 2025.
Is CRDF a buy based on overall technical signals summary?
CRDF has 4 buy signals and 5 sell signals now. Overall the technical rating for CRDF is Neutral . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of CRDF.
What is the trend of Cardiff Oncology Inc (CRDF)'s moving average?
Cardiff Oncology Inc's overall moving average trend leans more bearish as of June 20 2025, with 2 negative signals and 2 positive signal.
What is price prediction for CRDF stock next month?
The price prediction chart for Cardiff Oncology Inc (CRDF.O) stock, as of June 15 2025, forecasts a 1.06% change over the next month, based on its high correlation with TRV stock patterns. The similarity between their price movements over the analyzed periods is 98.43%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for CRDF Stock?
CRDF stock is predicted to reach **$18 by end of 2025**, driven by strong analyst sentiment and positive Phase 2 trial results. Analysts maintain a Strong Buy rating with a $13.33 average target, while recent trial data showing a 64% response rate supports further upside.
What is price prediction 2030 for CRDF Stock?
CRDF stock is predicted to reach $15 by 2030, driven by strong analyst sentiment and growth prospects in the oncology sector. The current price of $3.01, combined with a $13.33 average analyst target, suggests significant upside potential. Positive technical indicators and improving market optimism further support this bullish outlook.